Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.

Scutari R, Alteri C, Vicenti I, Carlo DD, Zuccaro V, Incardona F, Borghi V, Bezenchek A, Andreoni M, Antinori A, Perno CF, Cascio A, Luca A, Zazzi M, Santoro MM; ARCA (Antiviral Response Cohort Analysis) study Group.

J Glob Antimicrob Resist. 2019 Jul 19. pii: S2213-7165(19)30181-X. doi: 10.1016/j.jgar.2019.07.015. [Epub ahead of print]

PMID:
31330378
2.

Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium.

Vinken L, Fransen K, Cuypers L, Alexiev I, Balotta C, Debaisieux L, Seguin-Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sönnerborg A, Vancutsem E, Vandamme AM, Van den Wijngaert S, Van Ranst M, Verhofstede C, Stadler T, Lemey P, Van Laethem K.

Front Microbiol. 2019 Mar 26;10:613. doi: 10.3389/fmicb.2019.00613. eCollection 2019.

3.

Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics.

Sarfo FS, Castelnuovo B, Fanti I, Feldt T, Incardona F, Kaiser R, Lwanga I, Marrone G, Sonnerborg A, Tufa TB, Zazzi M, De Luca A.

J Infect. 2019 May;78(5):402-408. doi: 10.1016/j.jinf.2019.03.003. Epub 2019 Mar 6.

PMID:
30849438
4.

Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort.

Bavaro DF, Di Carlo D, Zuccalà P, Bai F, Incardona F, Battisti A, Giachè S, Salomoni E, Gagliardini R, Di Giambenedetto S, Pecorari M, Zazzi M, De Luca A, Bezenchek A, Lo Caputo S.

Infect Dis (Lond). 2019 Mar;51(3):234-239. doi: 10.1080/23744235.2018.1544423. Epub 2019 Jan 21. No abstract available.

PMID:
30663927
5.

PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context.

Libin P, Vanden Eynden E, Incardona F, Nowé A, Bezenchek A; EucoHIV Study Group, Sönnerborg A, Vandamme AM, Theys K, Baele G.

Bioinformatics. 2017 Dec 15;33(24):3993-3995. doi: 10.1093/bioinformatics/btx535.

6.

A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium.

Vinken L, Fransen K, Pineda-Peña AC, Alexiev I, Balotta C, Debaisieux L, Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sonnerborg A, Vancutsem E, Van den Wijngaert S, Van Ranst M, Verhofstede C, Vandamme AM, Lemey P, Van Laethem K.

Virus Evol. 2017 Mar 5;3(Suppl 1). pii: vew036.020. doi: 10.1093/ve/vew036.020. eCollection 2017 Mar. No abstract available.

7.

Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.

Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, Incardona F, Zazzi M, Sönnerborg A.

PLoS One. 2017 Jun 5;12(6):e0178942. doi: 10.1371/journal.pone.0178942. eCollection 2017.

8.

Registered report: Interactions between cancer stem cells and their niche govern metastatic colonization.

Incardona F, Doroudchi MM, Ismail N, Carreno A, Griner E, Anna Lim M; Reproducibility Project: Cancer Biology.

Elife. 2015 Jun 18;4:e06938. doi: 10.7554/eLife.06938.

9.

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.

Vingerhoets J, Calvez V, Flandre P, Marcelin AG, Ceccherini-Silberstein F, Perno CF, Mercedes Santoro M, Bateson R, Nelson M, Cozzi-Lepri A, Grarup J, Lundgren J, Incardona F, Kaiser R, Sonnerborg A, Clotet B, Paredes R, Günthard HF, Ledergerber B, Hoogstoel A, Nijs S, Tambuyzer L, Lavreys L, Opsomer M; Etravirine Cohort Study Group.

HIV Med. 2015 May;16(5):297-306. doi: 10.1111/hiv.12218. Epub 2015 Jan 14.

10.

HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure.

Sangeda RZ, Theys K, Beheydt G, Rhee SY, Deforche K, Vercauteren J, Libin P, Imbrechts S, Grossman Z, Camacho RJ, Van Laethem K, Pironti A, Zazzi M, Sönnerborg A, Incardona F, De Luca A, Torti C, Ruiz L, Van de Vijver DA, Shafer RW, Bruzzone B, Van Wijngaerden E, Vandamme AM; Virolab and EuResist Projects.

Infect Genet Evol. 2013 Oct;19:349-60. doi: 10.1016/j.meegid.2013.03.014. Epub 2013 Mar 21.

11.

Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes.

Rhee SY, Blanco JL, Liu TF, Pere I, Kaiser R, Zazzi M, Incardona F, Towner W, Gatell JM, De Luca A, Fessel WJ, Shafer RW.

AIDS Res Ther. 2012 May 3;9(1):13. doi: 10.1186/1742-6405-9-13.

12.

Predicting response to antiretroviral treatment by machine learning: the EuResist project.

Zazzi M, Incardona F, Rosen-Zvi M, Prosperi M, Lengauer T, Altmann A, Sonnerborg A, Lavee T, Schülter E, Kaiser R.

Intervirology. 2012;55(2):123-7. doi: 10.1159/000332008. Epub 2012 Jan 24. Review.

13.

A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.

Piotrowicz RS, Damaj BB, Hachicha M, Incardona F, Howell SB, Finlayson M.

Mol Cancer Ther. 2011 Nov;10(11):2072-82. doi: 10.1158/1535-7163.MCT-11-0351. Epub 2011 Sep 1.

14.

Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).

Zazzi M, Kaiser R, Sönnerborg A, Struck D, Altmann A, Prosperi M, Rosen-Zvi M, Petroczi A, Peres Y, Schülter E, Boucher CA, Brun-Vezinet F, Harrigan PR, Morris L, Obermeier M, Perno CF, Phanuphak P, Pillay D, Shafer RW, Vandamme AM, van Laethem K, Wensing AM, Lengauer T, Incardona F.

HIV Med. 2011 Apr;12(4):211-8. doi: 10.1111/j.1468-1293.2010.00871.x. Epub 2010 Aug 19. Erratum in: HIV Med. 2012 Apr;13(4):253.

15.

Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.

Frentz D, Boucher CA, Assel M, De Luca A, Fabbiani M, Incardona F, Libin P, Manca N, Müller V, O Nualláin B, Paredes R, Prosperi M, Quiros-Roldan E, Ruiz L, Sloot PM, Torti C, Vandamme AM, Van Laethem K, Zazzi M, van de Vijver DA.

PLoS One. 2010 Jul 9;5(7):e11505. doi: 10.1371/journal.pone.0011505.

16.

Only slight impact of predicted replicative capacity for therapy response prediction.

Weisser H, Altmann A, Sierra S, Incardona F, Struck D, Sönnerborg A, Kaiser R, Zazzi M, Tschochner M, Walter H, Lengauer T.

PLoS One. 2010 Feb 3;5(2):e9044. doi: 10.1371/journal.pone.0009044.

17.

Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype.

Altmann A, Sing T, Vermeiren H, Winters B, Van Craenenbroeck E, Van der Borght K, Rhee SY, Shafer RW, Schülter E, Kaiser R, Peres Y, Sönnerborg A, Fessel WJ, Incardona F, Zazzi M, Bacheler L, Van Vlijmen H, Lengauer T.

Antivir Ther. 2009;14(2):273-83.

PMID:
19430102
18.

Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization.

Prosperi MC, D'Autilia R, Incardona F, De Luca A, Zazzi M, Ulivi G.

Bioinformatics. 2009 Apr 15;25(8):1040-7. doi: 10.1093/bioinformatics/btn568. Epub 2008 Oct 31.

PMID:
18977781
19.

Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy.

Altmann A, Rosen-Zvi M, Prosperi M, Aharoni E, Neuvirth H, Schülter E, Büch J, Struck D, Peres Y, Incardona F, Sönnerborg A, Kaiser R, Zazzi M, Lengauer T.

PLoS One. 2008;3(10):e3470. doi: 10.1371/journal.pone.0003470. Epub 2008 Oct 21.

20.

Selecting anti-HIV therapies based on a variety of genomic and clinical factors.

Rosen-Zvi M, Altmann A, Prosperi M, Aharoni E, Neuvirth H, Sönnerborg A, Schülter E, Struck D, Peres Y, Incardona F, Kaiser R, Zazzi M, Lengauer T.

Bioinformatics. 2008 Jul 1;24(13):i399-406. doi: 10.1093/bioinformatics/btn141.

21.

Thrombospondin-1 expression in RPE and choroidal neovascular membranes.

He S, Incardona F, Jin M, Ryan SJ, Hinton DR.

Yan Ke Xue Bao. 2006 Dec;22(4):265-74.

PMID:
17378161
22.

Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity.

Prins RM, Incardona F, Lau R, Lee P, Claus S, Zhang W, Black KL, Wheeler CJ.

J Immunol. 2004 Feb 1;172(3):1602-11.

23.

Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.

Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL.

Cancer Res. 2001 Feb 1;61(3):842-7.

24.

HIV-1 tat protein induces the production of interleukin-8 by human brain-derived endothelial cells.

Hofman FM, Chen P, Incardona F, Zidovetzki R, Hinton DR.

J Neuroimmunol. 1999 Feb 1;94(1-2):28-39.

PMID:
10376933
25.

Endothelin-1 induces production of the neutrophil chemotactic factor interleukin-8 by human brain-derived endothelial cells.

Hofman FM, Chen P, Jeyaseelan R, Incardona F, Fisher M, Zidovetzki R.

Blood. 1998 Nov 1;92(9):3064-72.

PMID:
9787140
26.

Thrombospondin, a negative modulator of megakaryocytopoiesis.

Chen YZ, Incardona F, Legrand C, Momeux L, Caen J, Han ZC.

J Lab Clin Med. 1997 Feb;129(2):231-8.

PMID:
9016860
27.

Heparin-binding domain, type 1 and type 2 repeats of thrombospondin mediate its interaction with human breast cancer cells.

Incardona F, Lawler J, Cataldo D, Panet A, Legrand Y, Foidart JM, Legrand C.

J Cell Biochem. 1996 Sep 15;62(4):431-42.

PMID:
8891889
28.

How much are homologous peptides homologous?

Incardona F, Morante S, Parisi V, Rossi GC.

J Theor Biol. 1995 Aug 21;175(4):437-55.

PMID:
7475084
29.

Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species.

Ravanat C, Freund M, Dol F, Cadroy Y, Roussi J, Incardona F, Maffrand JP, Boneu B, Drouet L, Legrand C, et al.

Blood Coagul Fibrinolysis. 1995 Jul;6(5):446-55.

PMID:
8589212
30.

Thrombospondin modulates human breast adenocarcinoma cell adhesion to human vascular endothelial cells.

Incardona F, Lewalle JM, Morandi V, Lambert S, Legrand Y, Foidart JM, Legrand C.

Cancer Res. 1995 Jan 1;55(1):166-73.

31.

Involvement of thrombospondin in the adherence of human breast-adenocarcinoma cells: a possible role in the metastatic process.

Incardona F, Calvo F, Fauvel-Lafeve F, Legrand Y, Legrand C.

Int J Cancer. 1993 Sep 30;55(3):471-7.

PMID:
8375932

Supplemental Content

Loading ...
Support Center